Compare iShares iBoxx $ Inv Grade Corporate Bond ETF (LQD) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares iBoxx $ Inv Grade Corporate Bond ETF vs Novo Nordisk A/S — how do they compare? iShares iBoxx $ Inv Grade Corporate Bond ETF trades at $102.35 (market cap $28.50B), while Novo Nordisk A/S trades at $38.63 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 5.8× iShares iBoxx $ Inv Grade Corporate Bond ETF's market cap, and Novo Nordisk A/S pays a 4.71% dividend while iShares iBoxx $ Inv Grade Corporate Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares iBoxx $ Inv Grade Corporate Bond ETF for 125 Days and Novo Nordisk A/S for 116 Days on average.
| LQD | NVO | |
|---|---|---|
Market Cap | $28.50B | $165.31B |
Volume | 37,320,110 | 11,432,838 |
Sector | Fixed Income | Health |
52-Week High | $112.91 | $63.98 |
52-Week Low | $101.83 | $35.29 |
Typical Hold Time | 125 Days | 116 Days |
Enterprise Value | — | $179.56B |
Dividend Yield | — | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LQD trades at $102.39 with a slight 0.26% daily gain amid a challenging bond market environment. The ETF faces bearish technical signals with moving averages indicating downward pressure, though oscillators remain neutral. Recent news highlights significant short interest growth of 53.1% in September (Defense World, 2026-10-01) and concerns about investment-grade corporate bonds as Treasury yields hit multi-decade highs.
The outlook remains cautious with rising bond yields creating headwinds for corporate bond ETFs. While LQD offers a 4.8% yield with high-quality portfolio exposure, the weak investment thesis noted by Seeking Alpha (2026-09-22) and substantial short interest growth suggest near-term pressure. Investors should monitor Fed policy decisions and corporate bond market stability for directional cues.
Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.
NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares iBoxx $ Inv Grade Corporate Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in fixed income securities of the types included in the underlying index that the advisor believes will help the fund track the underlying index. The underlying index is designed to provide a broad representation of the US dollar-denominated liquid investment-grade corporate bond market.
Read more on LQD →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
